RxDoctor Payments Data

Carrie Quinlan

Family · Jackson, WYNPI 1942711254

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.8% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Medtronic at 56.7% of the total.

$1,674in general payments, 2019–2025

Across 62 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$950
  • AbbVie$510
  • Lundbeck LLC$135
  • Pfizer$56
  • Galderma Laboratories, L.p.$23

What the payments were for

  • Food & beverage$1,63898%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic27$950
AbbVie(2 entities)25$510
Lundbeck LLC6$135
Pfizer3$56
Galderma Laboratories, L.p.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,674 in reported general payments places this provider in the 85th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$33,238
Medicare patients
70
Services billed
1,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant30$49,863
QuliptaAtogepant13$13,756
OxycontinOxycodone Hcl37$11,067
Emgality SyringeGalcanezumab-Gnlm11$8,486
ButransBuprenorphine12$6,478
Oxycodone Hcl115$2,868
Fentanyl23$2,867
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$2,378
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen102$2,070
Ondansetron OdtOndansetron40$1,130
Morphine Sulfate ErMorphine Sulfate40$1,039
Pregabalin45$778
Gabapentin27$463
Sumatriptan Succinate38$309
Lorazepam44$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$510$63,62043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 284 family providers in Wyoming.

Other family in Jackson

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →